UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.073

Sortiert nach

Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab

Rheumatology (Oxford, England), 2018-06, Vol.57 (6), p.1128-1128

2018

Link zum Volltext

Verfügbarkeit prüfen

Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual

Lupus, 2007-01, Vol.16 (5), p.309-317

2007

Link zum Volltext

Verfügbarkeit prüfen

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

Lupus, 2010-07, Vol.19 (8), p.949-956

2010

Link zum Volltext

Verfügbarkeit prüfen

Atypical Bone Sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2016-04, Vol.68 (4), p.816-816

2016

Link zum Volltext

Verfügbarkeit prüfen

The Italian Society for Rheumatology recommendations for the management of axial spondyloarthritis

Reumatismo, 2021-08, Vol.73 (2), p.71-88

2021

Link zum Volltext

Verfügbarkeit prüfen

Consensus on the management of patients with psoriatic arthritis in a dermatology setting

Journal of the European Academy of Dermatology and Venereology, 2018-04, Vol.32 (4), p.515-528

2018

Link zum Volltext

Verfügbarkeit prüfen

The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases

International Journal of Immunopathology and Pharmacology, 2014-01, Vol.27 (1_suppl), p.1-10

2014

Link zum Volltext

Verfügbarkeit prüfen

FRI0175 Two-Year Retention Rate of Golimumab for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis of The Italian Lorhen Registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.492-493

2016

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab in the Treatment of Immune-Mediated Diseases

International Journal of Immunopathology and Pharmacology, 2014-01, Vol.27 (1_suppl), p.33-48

2014

Link zum Volltext

Verfügbarkeit prüfen

FRI0111 Change Over Time in the Pattern of Clinical Response to First-Line Biologic Drugs: Observational Data from a Local Registry

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.460-460

2015

Link zum Volltext

Verfügbarkeit prüfen

AB0806 Skeletal Dimorphisms are Independently Related to Musculo-Skeletal Discomfort in a Cohort of Psoriatic Subjects

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1169-1169

2015

Link zum Volltext

Verfügbarkeit prüfen

FRI0173 Role of Methotrexate as Combination Therapy with Adalimumab and Etanercept in Rheumatoid Arthritis: Retrospective Analysis from A Local Registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.492-492

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab

International Journal of Immunopathology and Pharmacology, 2014-01, Vol.27 (1_suppl), p.11-32

2014

Link zum Volltext

Verfügbarkeit prüfen

AB0462 The performance of new EULAR/ACR RA remission criteria in patients treated with biologic agents: Real-life experience

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.664-664

2013

Link zum Volltext

Verfügbarkeit prüfen

SAT0300 Nail psoriasis per se does not predict psoriatic arthritis: Analysis of risk factors in a cohort of italian psoriatic patients

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.573-573

2013

Link zum Volltext

Verfügbarkeit prüfen

Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA)

Reumatismo, 2016-12, Vol.68 (3), p.126-136

2016

Link zum Volltext

Verfügbarkeit prüfen

SAT0393 Distinguishing Spinal Diseases from Spondylitis among Psoriatic Subjects: the Performance of ASAS Inflammatory Back Pain Definition in A Mono-Centric CASE Series

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.736-736

2014

Link zum Volltext

Verfügbarkeit prüfen

FRI0497 Drug Retention and Pattern of Discontinuation of the First-Line Anti-TNF Drug in a Large Cohort of Patients with Adult or Juvenile-Onset Inflammatory Arthritides

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.608-609

2015

Link zum Volltext

Verfügbarkeit prüfen

FRI0232 Factors Influencing The Choice of First and Second Line Biologic Therapy for The Treatment of Rheumatoid Arthritis: Real Life Data from The Italian Lorhen Registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.517-517

2016

Link zum Volltext

Verfügbarkeit prüfen

SAT0391 The 8-Year Retention Rate of The First TNF-Inhibitor in The Treatment of Spondyloarthropathies: Real-Life Data from A Multicentric Local Registries

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.810-810

2016

Link zum Volltext

Verfügbarkeit prüfen

AB0731 Musculoskeletal but Not Skin Disease Activity Influence Rheumatologists Decision To Change Dmards or Biologic Therapy in Psoriatic Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1154-1154

2016

Link zum Volltext

Verfügbarkeit prüfen

AB0332 Golimumab Efficacy in Rheumatoid Arthritis after Conventional and Biological Treatment: Data from The Italian Lorhen Registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1014-1015

2016

Link zum Volltext

Verfügbarkeit prüfen

FRI0214 Six-Year Retention Rate of Abatacept in Rheumatoid Arthritis: A Multicentric Retrospective Analysis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.509-509

2016

Link zum Volltext

Verfügbarkeit prüfen

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

Journal of rheumatology, 2001-10, Vol.28 (10), p.2274

2001

Link zum Volltext

Verfügbarkeit prüfen

FRI0229 Survival on treatment of the second line biologic therapy: switch or swap strategy?

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A450-A451

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.073

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(817)
Mit Volltextzugriff
(907)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(679)
Physics
(324)
Humans
(322)
Physical Sciences
(312)
Life Sciences & Biomedicine
(266)
Female
(260)
Adult
(170)
Middle Aged
(147)
Physics, Multidisciplinary
(138)
Technology
(137)
Male
(122)
Exact Sciences And Technology
(120)
Rheumatology
(112)
Aged
(76)
Pregnancy
(75)
Engineering
(73)
Biological And Medical Sciences
(67)
Medical Sciences
(66)
Engineering, Electrical & Electronic
(65)
Physics, Mathematical
(57)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab

Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

Atypical Bone Sclerosis

The Italian Society for Rheumatology recommendations for the management of axial spondyloarthritis

Consensus on the management of patients with psoriatic arthritis in a dermatology setting

The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases

FRI0175 Two-Year Retention Rate of Golimumab for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis of The Italian Lorhen Registry

Adalimumab in the Treatment of Immune-Mediated Diseases

FRI0111 Change Over Time in the Pattern of Clinical Response to First-Line Biologic Drugs: Observational Data from a Local Registry

AB0806 Skeletal Dimorphisms are Independently Related to Musculo-Skeletal Discomfort in a Cohort of Psoriatic Subjects

FRI0173 Role of Methotrexate as Combination Therapy with Adalimumab and Etanercept in Rheumatoid Arthritis: Retrospective Analysis from A Local Registry

Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab

AB0462 The performance of new EULAR/ACR RA remission criteria in patients treated with biologic agents: Real-life experience

SAT0300 Nail psoriasis per se does not predict psoriatic arthritis: Analysis of risk factors in a cohort of italian psoriatic patients

Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA)

SAT0393 Distinguishing Spinal Diseases from Spondylitis among Psoriatic Subjects: the Performance of ASAS Inflammatory Back Pain Definition in A Mono-Centric CASE Series

FRI0497 Drug Retention and Pattern of Discontinuation of the First-Line Anti-TNF Drug in a Large Cohort of Patients with Adult or Juvenile-Onset Inflammatory Arthritides

FRI0232 Factors Influencing The Choice of First and Second Line Biologic Therapy for The Treatment of Rheumatoid Arthritis: Real Life Data from The Italian Lorhen Registry

SAT0391 The 8-Year Retention Rate of The First TNF-Inhibitor in The Treatment of Spondyloarthropathies: Real-Life Data from A Multicentric Local Registries

AB0731 Musculoskeletal but Not Skin Disease Activity Influence Rheumatologists Decision To Change Dmards or Biologic Therapy in Psoriatic Arthritis

AB0332 Golimumab Efficacy in Rheumatoid Arthritis after Conventional and Biological Treatment: Data from The Italian Lorhen Registry

FRI0214 Six-Year Retention Rate of Abatacept in Rheumatoid Arthritis: A Multicentric Retrospective Analysis

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

FRI0229 Survival on treatment of the second line biologic therapy: switch or swap strategy?

Suchergebnisse filtern